ArticleBMC infectious diseases2021
Infection pattern, case fatality rate and spread of Lassa virus in Nigeria.
Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Lassa fever in West Africa: a systematic review and meta-analysis of attack rates, case fatality rates and risk factors.BMC public health · 2025Pooled it
- Assessing the Environmental Drivers of Lassa Fever in West Africa: A Systematic Review.Viruses · 2025Pooled it
- In silico prioritization and cheminformatics identify structurally diverse small-molecule inhibitors of Lassa virus glycoprotein-mediated membrane fusion.SLAS discovery : advancing life sciences R & D · 2026Article
- Deadbolt Drug Discovery: Locking the Door to Class 1 Viral Entry by Small Molecules.ACS infectious diseases · 2026Review
- Local Knowledge of Land Use Effects on Human-Rodent Interfaces in Lassa-Endemic Nigeria.EcoHealth · 2026Article
- A fractional-order analysis of recurrent Lassa fever transmission in Nigeria.Virus research · 2026Article
- The Lassa virus fusion domain has structural plasticity and exploits bis(monoacylglycero)phosphate for fusion.Biophysical journal · 2026Article
- Lassa virus circumvents macrophage and dendritic cell antiviral defences in its natural reservoir, the Natal multimammate mouse (Mastomys natalensis).Npj viruses · 2026Article
- Temporal trends and epidemiological patterns of Lassa fever outbreaks in Ebonyi State, Nigeria: A retrospective study (2018-2023).PLOS global public health · 2026Article
- Viral zoonotic disease outbreaks and response strategies in Sub-Saharan Africa: a scoping review.One health outlook · 2025Review
- Genomic changes of Lassa virus associated with mammalian host adaptation.BMC genomics · 2025Article
- Detection of Immunoglobulin G and/or IgM antibodies specific for Lassa virus among HIV patients in the Northwestern region of Cameroon.Virology journal · 2025Article
- Impact of seasonal change on virus-rodent dynamics in NigeriaCurrent research in parasitology & vector-borne diseases · 2025Article
- Lassa fever in Nigeria: epidemiology and risk perception.Scientific reports · 2024Article
- Application of an Integrated Risk Matrix and the Borda Count Method on Lassa Fever in Assessing the Importation Risk of EID - 9 African Countries, 1996-2023.China CDC weekly · 2024Article
- Lassa Fever: Critical Review and Prospects for Control.Tropical medicine and infectious disease · 2024Review
- Modelling Lassa virus dynamics in West AfricanJournal of the Royal Society, Interface · 2024Article
- Systematic surveillance tools to reduce rodent pests in disadvantaged urban areas can empower communities and improve public health.Scientific reports · 2024Article
- Trend of Lassa fever cases and factors associated with mortality in Liberia, 2016 - 2021: a secondary data analysis.The Pan African medical journal · 2024Review
- Double stigma: a cross-sectional study of Lassa patients with hearing loss in North Central Nigeria.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLassa fever (LF) is a zoonotic infectious disease of public concern in Nigeria. The infection dynamics of the disease is not well elucidated in Nigeria. This study was carried out to describe the pattern of infection, case fatality rate and spread of lassa virus (LASV) from 2017 to 2020.
methodsWeekly epidemiological data on LF from December, 2016 to September, 2020 were obtained from Nigeria Centre for Disease Control. The number of confirmed cases and deaths were computed according to months and states. Descriptive statistics was performed and case fatality rate was calculated. Distribution and spread maps of LF over the four years period was performed on ArcMap 10.7.
resultsA total of 2787 confirmed cases and 516 deaths were reported in Nigeria from December, 2016 to September, 2020. Increase in number of cases and deaths were observed with 298, 528, 796 and 1165 confirmed cases and 79, 125, 158 and 158 deaths in 2017, 2018, 2019 and 2020 respectively. Over 60% of the cases were reported in two states, Edo and Ondo states. The LF cases spread from 19 states in 2017 to 32 states and Federal Capital Territory (FCT) in 2020. Ondo state (25.39%) had the highest of deaths rate from LF over the four years. Case fatality rate (CFR) of LF was highest in 2017 (26.5%) with CFR of 23.7, 19.6 and 13.4% in 2018, 2019 and 2020 respectively. The peak of infection was in the month of February for the four years. Infections increases at the onset of dry season in November and decline till April when the wet season sets-in.
conclusionThere is an annual increase in the number of LASV infection across the states in Nigeria. There is need to heighten control strategies through the use of integrated approach, ranging from vector control, health education and early diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.